Compare WHG & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHG | TLSA |
|---|---|---|
| Founded | 1983 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.2M | 155.3M |
| IPO Year | 2002 | 2017 |
| Metric | WHG | TLSA |
|---|---|---|
| Price | $17.99 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.0K | ★ 284.5K |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.58% | N/A |
| EPS Growth | ★ 203.85 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $97,762,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $201.33 | ★ N/A |
| Revenue Growth | ★ 3.21 | N/A |
| 52 Week Low | $14.70 | $1.04 |
| 52 Week High | $18.99 | $2.60 |
| Indicator | WHG | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 67.40 | 31.09 |
| Support Level | $15.72 | N/A |
| Resistance Level | $18.64 | $1.61 |
| Average True Range (ATR) | 0.71 | 0.10 |
| MACD | 0.14 | -0.03 |
| Stochastic Oscillator | 81.43 | 2.27 |
Westwood Holdings Group Inc manages investment assets and provides services for clients through subsidiaries. It operates its business through the Advisory and Trust segments. Its Advisory segment provides investment advisory services to corporate retirement plans, public retirement plans, endowments, foundations, individuals and the Westwood Funds, as well as investment sub-advisory services to mutual funds and its trust segment. The Trust segment offers trust and custodial services to its clients and its advisory segment sponsors common trust funds to institutions and high net-worth individuals. It generates maximum revenue from the Advisory segment. Geographically, it derives a majority of its revenue from the United States, and also has its presence in Canada.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.